Home > Rheumatology > ACR 2020 > Late-Breaking News > New agent with great potential for the treatment of giant cell arteritis in the pipeline

New agent with great potential for the treatment of giant cell arteritis in the pipeline

Presented By
Dr Maria Cinta Cid, Hospital Clínic of Barcelona, Spain
Conference
ACR 2020
Lower risk of flare and increased sustained remission with mavrilimumab compared with placebo were the main results of a trial for giant cell arteritis with the novel anti-GM-CSF receptor alpha monoclonal antibody. “A substantial proportion of patients treated with tocilizumab fail treatment due to relapse or tocilizumab-related side effects. IL-6 blockade may primarily target the Th17 axis, possibly leaving significant residual Th1 activity,“ Dr Maria Cinta Cid (Hospital Clínic of Barcelona, Spain) described the current situation in the treatment of giant cell arteritis (GCA). She observed a great unmet need for new treatments in GCA [1]. Dr Cid presented a phase 2, randomised, placebo-controlled study investigating mavrilimumab in patients with new-onset (N/O) or relapsing refractory (R/R) GCA. All patients had to be in corticosteroid-induced remission when starting the trial, meaning: no clinical symptoms, C-reactive protein (CRP) <1 mg/dL and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on